S5 Ep48: Moore Voices Excitement With VS-6766 Plus Defactinib in Ovarian Cancer
OncLive® On Air - Un pódcast de OncLive® On Air
Dr. Moore discusses the basis for studying the combination of VS-6766 and defactinib in recurrent low-grade serous ovarian cancer, data that has been generated with the combination from the phase 1/2 FRAME trial, and the potential role for the combination in clinical practice.
